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Abstract
Background: BMP signaling pathway is critical for vertebrate development and tissue homeostasis. High-throughput
molecular genetic screening may reveal novel players regulating BMP signaling response while chemical genetic screening
of BMP signaling modifiers may have clinical significance. It is therefore important to generate a cell-based tool to execute
such screens.
Methodology/Principal Findings: We have established a BMP responsive reporter cell line by stably integrating a BMP
responsive dual luciferase reporter construct in the immortalized calvarial osteoblast cells isolated from tamoxifen inducible
Bmp2; Bmp4 double conditional knockout mouse strain. This cell line, named BRITER (BMP Responsive Immortalized
Reporter cell line), responds robustly, promptly and specifically to exogenously added BMP2 protein. The sensitivity to
added BMP may be further increased by depleting the endogenous BMP2 and BMP4 proteins.
Conclusion: As the dynamic range of the assay (for BMP responsiveness) is very high for BRITER and as it responds
specifically and promptly to exogenously added BMP2 protein, BRITER may be used effectively for chemical or molecular
genetic screening for BMP signaling modifiers. Identification of novel molecular players capable of influencing BMP
signaling pathway may have clinical significance.
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Introduction
Bone Morphogenetic Protein (BMP) activity is the molecular
basis of the intrinsic regenerative ability of bone [1]. BMPs are
members of the transforming Growth Factor-b (TGF-b) super-
family of signaling molecules [2]. So far 20 different BMP
molecules have been identified in the humans [3,4] of which
BMP2, BMP4, BMP5, BMP6 and BMP7 are characterized as
osteogenic BMPs due to their ability to induce ectopic bone
formation [5]. It is known that Bone Morphogenetic Proteins
(BMPs) are necessary and sufficient for bone formation [1,6]. BMP
ligands bind to typeI and typeII serine/threonine kinase cell
surface receptors. Upon ligand binding, the typeII receptors
phosphorylate type I receptors which in turn phosphorylate a
group of transcription factors known as receptor-regulated
SMADs (R-SMADs) i.e. SMAD1, SMAD5 or SMAD8. Phos-
phorylated R-SMADs form a heterodimer with SMAD4 and
translocate into the nucleus and regulate transcription of a host of
BMP downstream target genes [7,8,9]. One well characterized
BMP downstream target is inhibitor of differentiation-1 (Id1).
Korchynski et. al. characterized the promoter region of Id1 and
defined a minimal DNA sequence that is responsive to BMP
signaling and named it as BMP responsive element (BRE) [10].
BRE consists of SMAD binding elements (SBEs) along with a
GGCGCC palindrome. Multimerization of these elements gener-
ates a sensitive, BMP-specific enhancer [10]. BRE has been well
characterized in different laboratories and in different cell lines
[11,12,13,14]. It has been demonstrated that BRE responds
specifically to BMP signaling and not to the related pathways such
as TGF-b signaling [10].
Occurrence of bone fracture and spinal injuries is quite
commonplace. While most fractures heal on their own due to
the intrinsic regenerative capacity of bone, a significant problem
arises for complex fractures particular those in the elderly.
Standard of care for complex fractures involves surgery along
with metallic nails to hold pieces of bone together
[15,16,17,18,19]. However, even under these conditions a
common problem is non-union or delayed union of the fracture
site resulting in impaired healing. Recombinant BMP2 and BMP7
proteins are used routinely for fracture healing treatment [20,21].
BMPs have multiple effects on tissues other than bone and exert
their effects through finely regulated events involving local
production, storage and activation at appropriate time and site.
Hence systemic administration of BMPs may cause unwarranted
side effects. Further, due to rapid clearance of BMPs by the
circulatory system its systemic residence time in vivo is very short
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are used for in situ BMP delivery [23,24]. Also BMPs have very
short half lives in vivo [25]. The labile nature of BMPs coupled
with the necessity to use specialized devices for BMP delivery for
clinical purposes makes this therapy very expensive and limited in
its scope.
A small molecule agonist of BMP signaling might serve as a
substitute for clinical applications of BMPs to circumvent the
issues associated with the use of BMP protein for therapeutic
purposes. Such molecules may be identified through a high-
throughput functional genetic or chemical genetic screen using a
BMP-responsive reporter cell line. Although different BMP-
responsive reporter cell lines have been previously reported in the
literature these cell lines suffer from certain shortcomings such as
lack of internal control and prolonged exposure time required for
response to exogenous BMP [11,12,13,14]. These limitations may
potentially increase the number of false positives identified in a
screen. Thus we have established a BMP responsive reporter cell
line to address some of these shortcomings. This cell line is
constructed by stably transfecting a BMP responsive dual
luciferase reporter construct in the immortalized calvarial
osteoblast cells isolated from tamoxifen inducible Bmp2; Bmp4
double conditional knockout mouse strain. In this cell line the
endogenous level of BMP signaling can be reduced by treatment
with 4-hydroxytamoxifen (4-OHT) to increase the sensitivity of
the assay. The reporter construct contains BRE driven Firefly
Luciferase gene (FFLuc) and SV40 promoter/enhancer driven
Renilla luciferase (RRLuc) gene, to serve as an internal
normalization control for cell number as well as non specific
transcription activation. This cell line, named BRITER (BMP
Responsive Immortalized Reporter cell line), undergoes osteo-
genic differentiation in response to exogenous BMP and
specifically reports BMP signaling activity in a robust and
sensitive manner.
Materials and Methods
Generation of tamoxifen inducible Bmp2; Bmp4 double
conditional knockout mice
Bmp2; Bmp4 double conditional knockout mouse strain(Bmp2
C/C;
Bmp4
C/C) has been described before [6]. Tamoxifen inducible
B6;129-Gt(ROSA)26Sor
tm1(cre/ERT)Nat/J mouse strain, was imported
from Jackson Laboratories, U.S.A. (Stock no. 004847) [26]. Here
after this strain is referred to as R26CreER. Tamoxifen inducible
Bmp2; Bmp4 double conditional knockout mouse strain was
generated in this study. Bmp2
C/C; Bmp4
C/C was crossed with
R26CreER for two rounds to generate Bmp2
C/C; Bmp4
C/C;
R26creER/R26CreER. This strain behaved as wild type and can
be rendered BMP2 and BMP4 deficient upon administration of
Tamoxifen (2.5 mg/20 g body weight for seven days) (data not
shown).
All animal experiments were done according to the protocol
approved by institute animal ethics committee which is registered
with CPCSEA (reg. no. 810/03/ac/CPCSEA, dated 15/10/
2003).
Construction of BMP responsive reporter vector
BMP Responsive Element sequence was described and charac-
terized by Korchynski et.al [10]. This BRE sequence was cloned in
pGL3-Promoter vector (Promega). Briefly, two oligos as described
below were synthesized.
BRE For NheI 59-39
CTAGCTCAGACCGTTAGACGCCAGGACGGGCTGT-
CAGGCTGGCGCCGGATCTAGCTCAGACCGTTA-
GACGCCAGGACGGGCTGTCAGGCTGGCGCCGA
With NheI overhang and BRE Rev BglII 59-39
GATCTCGGCGCCAGCCTGACAGCCCGTCCTGGCGT-
CTAACGGTCTGAGCTAGATCCGGCGCCAGCCTGACAG-
CCCGTCCTGGCGTCTAACGGTCTGAG
with BglII overhang.
The oligos were annealed and cloned in pGL3-Promoter vector
between NheI and BglII sites to create pGL3-BRE-FFLuc vector.
BRE-FFLuc cassette was excised from pGL3-BRE-FFLuc using
NheI and BamHI restriction enzymes and cloned into pGL4.28
vector (Promega) between NheI and BamHI restriction sites to
create pGL4.28-BRE-FFLuc vector.
Internal Ribosomal Entry Site (IRES) was PCR amplified from
pCAGIG vector (Addgene No. 11159) using Pfu DNA polymerase
with primers
AB383-Forward (59-AATAGCCGCTACGTAAATTCCG-39)
and AB384-reverse (59-TACGCGTTAGCCGTCATATGATA-
TTATCATCGTGTTTT-39) where nucleotides denoted in bold
letters indicate IRES specific sequence and reverse primer
contains MluI (single underlined) and NdeI (double underlined)
restriction enzyme sites. The blunt ended PCR product was cloned
into PmeI linearized pGL4.28-BRE-FFLuc and the construct was
named pGL4.28-BRE-FFLuc-IRES. Subsequently Renilla lucif-
erase coding region was PCR amplified from pGL4.84 vector
(Promega, U.S.A.) using primers
AB381-Forward (ATAATAGCATATGGCTTCCAAGGTG-
TACGAC) containing NdeI restriction enzyme site (single under-
lined) and AB382-reverse (ATAAATTACGCGTTTAGACGTT-
GATCCTGGCG) containing MluI restriction enzyme site (single
underlined). Purified PCR product was digested and cloned into
NdeI and MluI site of pGL4.28-BRE-FFLuc-IRES construct
resulting in the creation of BMP responsive dual luciferase
reporter construct pGL4.28-BRE-FFLuc-IRES-RRLuc or pBFIR
(Figure1).
Isolation of calvarial osteoblast cells
Primary calvarial osteoblasts were isolated as previously
described [20]. Briefly, calvaria were isolated from 2–3 day old
neonatal mice, washed with phosphate buffered saline (PBS)
followed by digestion with 0.1% collagenase and 0.2% dispase at
37uC (five times for 10 minutes each). The last three groups of
fractionated cells were collected and maintained in a-Minimum
Essential Medium (Sigma Aldrich) containing 10% fetal bovine
serum (FBS) (Invitrogen, U.S.A.) with 100 U/ml penicillin G and
100 mg/ml streptomycin and cultured at 37uC in a humidified
atmosphere of air containing 5% CO2. Unless otherwise
mentioned, a-MEM with 10% FBS, 100 U/ml penicillin G and
100 mg/ml streptomycin is referred to as the standard media in
this report.
Retroviral Immortalization of primary osteoblast cells
Primary calvarial osteoblast cells were immortalized through
infection with a retrovirus expressing SV40 large T-Antigen [27].
Briefly, 293T cells were co-transfected with pBabe-Puro-SV40 LT
retroviral vector [28] and pCL-10A1 packaging vector (Imagenex,
U.S.A.) using Superfect transfection reagent following manufac-
turer’s protocol (Fermentas). Fresh media was added 24 hours
after transfection and the culture supernatant containing retrovirus
was collected every 24 hours, filtered and was directly used to
infect the primary osteoblast cells at passage three. 48 hours after
infection, virus containing media was replaced with fresh media.
72 hours post-infection, osteoblast cells were cultured in standard
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Aldrich) for another two weeks. Well isolated drug resistant
colonies were further re-plated at very low density to obtain single
cell derived colonies. Several colonies were expanded into cell lines
and eventually the one displaying osteogenic activity comparable
to uninfected primary osteoblasts was chosen for further manip-
ulation. This Tamoxifen inducible Bmp2; Bmp4 double conditional
knockout osteoblast cell line is named BDO17 (Bmp2/4 Deplet-
able Osteoblast Clone #17) cell line.
Creation of BMP responsive reporter osteoblast cell line
BMP responsive dual luciferase reporter vector, pBFIR, was
linearized with BamHI and transfected into BDO17 cells. Briefly,
20 mg of linearized pBFIR was transfected into the BDO17cells in
a 100 mm plate using standard calcium phosphate method [29].
24 hours later, cells were replenished with fresh media and
allowed to grow for 48 hours. Transfected osteoblast cells were
cultured in standard medium supplemented with 100 mg/ml of
Hygromycin B (Invitrogen, U.S.A.) for another two weeks. Well
Figure 1. Creation of BRITER Cell Line. (A) Schematic showing steps involved in the creation of BRITER Cell Line. (B) Schematic showing critical
genetic components of BRITER Cell Line. (C) BMP2 dependent FFLuc activity of BRITER Cell Line under four different conditions, namely ‘‘2BMP. 24-
OHT’’, ‘‘2BMP, +4-OHT’’, ‘‘+BMP, +4-OHT’’ and ‘‘+BMP, 24-OHT’’. (D) Anti-PSMAD 1/5/8 immunofluorescence in BRITER cell line under four different
conditions: (a) 2BMP24-OHT, (b) 2BMP+4-OHT, (c) +BMP+4-OHT and (d) +BMP24-OHT. Scale bar 100 mm. (E) Quantification of Anti-PSMAD 1/5/8
immunofluorescence by Image J. (F) Western blot analysis of BRITER cell extracts cultured under indicated conditions with PSMAD 1/5/8 antibody. b-
tubulin antibody has been used as loading control. Data shown are means 6 SEM of three independent experiments carried out in triplicates.
doi:10.1371/journal.pone.0037134.g001
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density to obtain single cell derived colonies. Several clones were
expanded into cell lines and checked for their BMP responsiveness
after several passages and freeze thaw cycles. Based on maximal
responsiveness of FFLuc and minimal responsiveness of RRLuc to
exogenously added BMP, clone number 7 was used for further
study. Hereafter, this cell line is referred to as BRITER (BMP
Responsive Immortalized Reporter cell line). Most of the assays
with BRITER cells were conducted at 25 passages unless
otherwise mentioned.
Alkaline phosphatase activity
For detecting alkaline phosphatase activity [30,31], BRITER
cells were cultured in 12-well plate containing mineralization
medium (Standard medium containing 50 mg/ml ascorbic acid
and 10 mM sodium b-glycerophosphate) for 2 weeks. Where
indicated, cells were treated with 4-OHT (1 mM) and/or BMP2
(100 ng/ml) (Sino Biologicals, China) for the duration of the
experiment. After two weeks of culturing, cells were washed with
PBS. 500 ml of Fixation solution (citrate buffer, 60% acetone, 10%
methanol) was added to each well and kept at room temperature
for 5 minutes. The fixed monolayer was washed with cold distilled
water and incubated with 5-Bromo-4-chloro-3-indolyl phosphate/
Nitroblue tetrazolium chloride (BCIP/NBT) liquid substrate
system (Roche) [1 ml of NBT (50 mg/ml)+1 ml of BCIP (25 mg/
ml) in 1000 ml of NTM buffer, pH 9.5]. The reaction was stopped
by removing the substrate solution and washing 3 times with cold
distilled water. Cells were examined under the microscope (Leica
DMIL-LED) and photographed (Leica DFC290).
For quantitative estimation of alkaline phosphatase activity we
performed colorimetric assay using a chromogenic substrate of
alkaline phosphatase, namely p-nitrophenyl phosphate (pNPP,
Sigma Aldrich, Cat No. P7998). The assay was conducted as per
manufacturer’s protocol. In short, 10
6 BRITER cells were plated
in 6 cm dishes containing mineralization medium (Standard
medium containing 50 mg/ml ascorbic acid and 10 mM sodium
b-glycerophosphate) and cultured for 2 weeks. Where indicated,
cells were treated with 4-OHT (1 mM) and/or BMP2 (100 ng/ml)
(Sino Biologicals, China) for the duration of the experiment. After
two weeks of culturing, cells were washed with PBS, 1 ml of pNPP,
ready-to-use, substrate was added to each of the plates. The plates
were incubated at 37uC for 30 minutes. The production of p-
nitrophenol was measured at 405 nm absorbance in microplate
reader. Alkaline phosphatase activity is expressed as nmol of
product/minute/10
6 cells. 1 absorbance unit is equal to 64 nmol
of p-nitrophenol. The assay was done in triplicate for all the four
different culture conditions.
Alizarin red and von Kossa staining
For alizarin red staining, BRITER cells were fixed in cold 70%
ethanol for 1 hour at 4uC. The fixed monolayer was washed with
cold distilled water and stained with a fresh 2% Alizarin Red S
solution (pH 4.2) for 5 minutes at room temperature [32]. The cell
layers were then washed with deionized water and photographed.
For von Kossa staining [33], the cells were rinsed with PBS and
fixed with 10% neutral buffered formalin solution for 30 minutes.
After washing with water, the cells were incubated with freshly
prepared 5% silver nitrate solution in distilled water for 45 min at
room temperature under 100 watt light source. The silver nitrate
stain was developed with freshly prepared 5% sodium carbonate in
25% neutral buffered formalin for 2–5 minutes, until the bone
nodules turned black. Finally, the cells were washed again with
water and treated with 5% sodium thiosulphate for 2 minutes.
The samples were rinsed in water and the bone nodules were
observed under the microscope and photographed.
RNA preparation and reverse transcription-polymerase
chain reaction
BRITER cells were cultured in mineralization media for 2
weeks. Total RNA was extracted using Tri-reagent (Sigma
Aldrich) and treated with DNAseI (Promega U.S.A.). 5 mg of total
RNA was reverse transcribed into cDNA using ImProm-II
TM
Reverse Transcription System (Promega U.S.A.). Specific primers
for the RT-PCR of osteoblast markers e.g. Osterix (Osx), collagen,
type I, alpha 1 (Col1A1), Bone sialoprotein (BSP) Runt-related
transcription factor 2 (Runx2), Osteocalcin (OCN), Alkaline
Phosphatase (ALP) and Gapdh are described in (Table S1). A
primer pair for SV40 large T-Antigen was also used to determine
stable integration and expression of the immortalizing gene.
4-Hydroxytamoxifen mediated recombination
BRITER cells were cultured in 100 mm tissue culture plates
with and without 4-Hydroxytamoxifen (1 mM) for 24 hours.
Genomic DNA and total RNA was isolated from the cells.
Genomic DNA PCR was carried out using primers described in
Table S1 and Figure S2A. Change in the abundance of Bmp2 and
Bmp4 mRNA was examined through RT-PCR using primers
described in Table S1. Amplicon for Cre transgene was used a
loading control for genomic DNA PCR while Gapdh mRNA was
used as a loading control for RT-PCR experiment.
Phospho-SMAD 1/5/8 immunofluorescence
BRITER cells were plated in 12 well tissue culture plate and
treated with 4-OHT (1 mM) and/or BMP2 (100 ng/ml) for
24 hours as indicated. Cells were washed with PBS followed by
treatment with hydrogen peroxide (3%) for 5 minutes at room
temperature. After washing with PBT (PBS+ 0.5% Tween-20) cells
were incubated in blocking solution (5% heat inactivated goat
serum in PBT) for 1 hour at room temperature. Primary antibody
against PSMAD 1/5/8 (Cell Signaling, U.S.A.) was added at
1:100 dilution in blocking solution for 16 hours at 4uC. Cells were
washed with PBS and incubated with Cy3-conjugated anti-rabbit
IgG (Jackson Immunoresearch, U.S.A.) in PBS for 2 hours at
room temperature. After washing with PBS, cells were counter-
stained with DAPI and mounted in Vectashield antifade reagent
(Vector Laboratories, U.S.A.). Quantification of average PSMAD
1/5/8 immunoreactivity was carried out using Image J software
(NIH). For each analysis three independent plates were included
for each of the four culture conditions and five different fields were
photographed from each of the plates. The experiment was
repeated three times. The data is presented as average intensity of
anti-PSMAD 1/5/8 immunofluorescence.
Phospho SMAD 1/5/8 Western blot
For Western blot detection of PSMAD 1/5/8, lysates were
prepared from BRITER cells cultured as above. The lysis buffer
(50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 1% DOC,
0.1% SDS 1 mM PMSF and 1 mM EDTA) contained protease
inhibitor cocktail (Sigam-Aldrich) and phosphatase inhibitor
cocktail (Calbiochem). Total protein from each lysates was
estimated using Bradford method. 30 mg protein for each sample
was resolved by SDS-PAGE (10%). The resolved proteins were
transferred onto nitrocellulose membrane and blocked with 5%
BSA. PSMAD 1/5/8 was detected by incubating the membrane
with antibody against PSMAD 1/5/8 (Cell Signaling, U.S.A.) at
1:1000 dilution for 4 hours at room temperature followed by
BMP Responsive Osteoblast Reporter Cell Line
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coupled to Horse Radish Peroxidase (Jackson Immunoresearch).
The signal was detected by enhanced chemiluminescence detec-
tion kit (ECL, Pierce). Anti-b-tubulin (1:5000, Sigma) was used as
loading control.
Dual Luciferase Assay
For C2C12 cells, the cells were transiently transfected with
pBFIR dual luciferase reporter construct using Fugene-HD
(Promega) following manufacturer’s protocol. The transfected
cells were cultured in standard medium for 24 hours. After
24 hours the culture medium was changed to a-MEM containing
0.1% FBS. Six hours later, cells were supplemented with 100 ng/
ml of recombinant BMP2 protein for indicated time periods. Dual
luciferase assay was carried out as per manufacturer’s recommen-
dation (Promega U.S.A). Three independent experiments were
done in triplicates. It should be noted that the cells were
maintained in a-MEM containing 0.1% FBS during the incuba-
tion period with recombinant BMP2 protein.
BRITER cells were plated in 24 well culture plate supplemented
with standard medium. When the cells were 70% confluent, the
wells were supplemented with regular medium containing 1 uM 4-
OHT or vehicle (Ethanol). 18 hours later the culture medium was
changed to a-MEM containing 0.1% FBS and 4-OHT as
indicated. Six hours later cells were supplemented with indicated
amount of recombinant BMP2 protein for indicated length of
time. Dual luciferase assay was carried out as per manufacturer’s
recommendation (Promega U.S.A). All experiments were done in
triplicates. It should be noted that cells were maintained in a-
MEM containing 0.1% FBS and 4-OHT (where indicated) during
the incubation period with recombinant BMP2 protein.
Results
Design and construction of BRITER cell line
The objective of this work was to construct a reporter cell line
that will specifically report BMP signaling activity for the purpose
of high-throughput functional genetic or chemical genetic
screening of BMP signaling modifiers. For this purpose we wanted
to take advantage of a well characterized BMP responsive
enhancer named BRE [10]. The response of osteoblast cells to
BMP signaling is very well studied [34,35]. Recently, a transgenic
mouse expressing BRE-lacZ was reported [36]. This mouse was
shown to express beta-galactosidase gene in the developing mouse
bone demonstrating that BRE is active in osteoblast cells in vivo.
We therefore, went ahead to use osteoblast cells for the purpose of
constructing the reporter cell line. However, osteoblast cells
themselves are known to produce a variety of BMPs [37,38] and
production of endogenous BMP by the reporter cell line is
expected to reduce its sensitivity towards exogenously added BMP
as well as reduce the dynamic range of the assay. Therefore, we
decided to engineer an osteoblast cell line which can be depleted of
endogenous BMPs to a large extent. For this purpose, we
generated an immortalized calvarial osteoblast cell line from
tamoxifen-inducible Bmp2; Bmp4 double knockout mouse strain.
This cell line was named as BDO17 (Please see Materials and
Methods and Figure 1A).
FFLuc activity provides quantitative readout and is amenable to
high throughput assays. Further, it has been used earlier as readout
of BRE activity in osteogenic cells [11]. We therefore cloned FFLuc
gene downstream of BRE enhancer. In published reports, BRE
responsiveness to exogenously added BMP has been assessed by
normalized FFLuc activity i.e. the ratio of FFLuc activity in the
presence and absence of exogenously added BMP [11,12,13,14]
(also see Table 1). Thisis a very sensitive and reliable assay for BMP
activity if pure BMP is used. However, in a chemical or molecular
genetic screen, cellular components other than BMP signaling
pathway may be perturbed, e.g. basic transcription, translation, cell
proliferation etc. This would give rise to altered FFLuc activity in
treated cells compared to untreated cells leading to false-positive
indications. To circumvent this problem it is essential to have an
inbuilt internal control. To the best of our knowledge no BMP-
responsiveosteogeniccelllinehasbeengeneratedtilldatewhichhas
such an in-built internal control. The most commonly used internal
control for such purposes is to use Renilla luciferase (RRLuc) gene
driven by a constitutive promoter. In the published literature dual
luciferase assays are generally conducted by co-transfection of two
constructs, one containing FFLuc gene and the other containing
RRLucgene.However,inviewofthepoortransfectionefficiencyof
BDO17 cells and to ensure the reproducibility of the assay we
decided to combine both the reporter genes in the same construct.
However, in such a construct the RRLuc gene would be in close
proximity to BRE enhancer and therefore a possibility exists that
RRLucactivitywouldalsobecomeresponsivetoexogenouslyadded
BMP protein. To examine this possibility, the dual luciferase
construct was first transiently transfected in C2C12 cells and tested
for two criteria: (1) BRE-FFLuc is responsive to exogenously added
BMP2 and (2) RRLuc activity driven by SV40 promoter is not
responsive to exogenously added BMP. We observed that the
stimulation of relative luciferase activity in response to exogenously
added BMP is approximately 18 fold comparable to an earlier
described report where dual luciferase assay was conducted by
transient co-transfcetion of two constructs [36] in C2C12 cell line
(Blue line, Figure S1). We observed4 fold stimulation of normalized
luciferase activity upon addition of exogenous BMP2 protein to
C2C12cellstransientlytransfectedwiththedualluciferaseconstruct
(Red line, Figure S1). The normalized luciferase activity observed
with our dual luciferase construct is comparable to some of the
earlier reported cell lines where the assay was conducted in C2C12
cells stably transfected with BRE-FFLuc construct [12,14] (also see
Table 1). Further, we did not observe any significant change in
RRLuc activity upon BMP addition (Green line, Figure S1). Once
the construct was verified, it was stably integrated into BDO17 cells
to generate BRITER cell line (BMP Responsive Immortalized
Reporter cell line).
Characterization of BRITER cell line
We first wanted to investigate whether BRITER cells can be
depleted of endogenous BMP activity upon 4-OHT treatment. For
this purpose we cultured the cells for 24 hours in presence or
absence of 4-OHT. Genomic DNA and total RNA was isolated
from the 4-OHT treated and untreated cells to investigate
recombination of Bmp2 and Bmp4 loci as well as abundance of
Bmp2 and Bmp4 mRNA. We observed that 24 hours of 4-OHT
treatment caused significant recombination of Bmp2 and Bmp4 loci
(Figure S2B) along with concomitant decrease in the correspond-
ing mRNA molecules (Figure S2C). To assess the status of BMP
signaling in these cells, before and after BMP depletion, we
cultured the cells for 24 hours under the following four conditions:
(1) in the absence of exogenous BMP2 protein as well as 4-OHT
(2BMP224-OHT), (2) in the absence of exogenous BMP2 protein
but with 4-OHT (2BMP2+4-OHT), (3) in the presence of
exogenous BMP2 protein and 4-OHT (+BMP2+4-OHT) and (4)
in the presence of exogenous BMP2 protein but absence of 4-
OHT (+BMP224-OHT). In the conditions 3 and 4, the amount
of BMP2 protein added was 100 ng/ml for a period of 3 hours. In
these cells, cultured under the four conditions, we measured
FFLuc activity as well as anti-PSMAD 1/5/8 immunoreactivity, a
BMP Responsive Osteoblast Reporter Cell Line
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FFLuc activity in the untreated cells (2BMP24-OHT) which was
reduced upon 4-OHT treatment (compare the bars for
‘‘2BMP24-OHT’’ and ‘‘2BMP+4-OHT’’ in Figure 1C). It is
likely that this reduction in FFLuc activity is due to the lowering of
endogenous BMP levels by the addition of 4-OHT. We observed
significant increase in FFLuc activity when BMP was added to 4-
OHT treated cells (compare the bars for ‘‘2BMP+4-OHT’’ and
‘‘+BMP+4-OHT’’ in Figure 1C). Maximum FFLuc activity was
observed when BMP was added to 4-OHT untreated cells
(compare the bars for ‘‘+BMP+4-OHT’’ and ‘‘+BMP24-OHT’’
in Figure1C). Next we examined PSMAD 1/5/8 immunofluores-
cence (Figure 1D) in the cells cultured under different conditions
and quantified the same using Image J software (Figure 1E). We
observed a basal level of PSMAD 1/5/8 immunoreactivity in the
untreated BRITER cells which was reduced upon 4-OHT
treatment (compare Figure 1D, panel a with figure 1D, panel b
and Figure 1E). We observed significant increase in PSMAD 1/5/
8 immunoreactivity when BMP was added to 4-OHT treated cells.
Maximum PSMAD 1/5/8 immunoreactivity was observed when
BMP was added to cells not treated with 4-OHT (compare
Figure1D, panel c with Figure1D, panel d and Figure 1E). We
have also analysed the abundance of PSMAD 1/5/8 by Western
blot analysis of lysates of BRITER cells cultured under the
different conditions described above (Figure 1F). The Western blot
data confirms that BRITER cells have low basal level of PSMAD
1/5/8 which may be stimulated by addition of exogenous BMP2
protein (compare lanes 2BMP24-OHT with +BMP24-OHT).
The maximum abundance of PSMAD 1/5/8 was observed when
recombinant BMP2 protein was added to 4-OHT untreated
BRITER cells (compare lanes +BMP24-OHT with +BMP+4-
OHT). We have observed a slight decrease in basal level FFLuc
activity as well as PSMAD 1/5/8 immunofluorescene upon
addition of 4-OHT to BRITER cells (see above). However, we
could not detect any reduction of PSMAD 1/5/8 abundance upon
4-OHT addition by Western blot ((compare lanes 2BMP24-
OHT with 2BMP+4-OHT). The reason for this apparent
anomaly is not clear. In this context it may also be noted that
we have also observed depletion of endogenous level of ALP
activity of BRITER cells upon 4-OHT treatment (please see
below). We next characterized the BRITER cells for several
criteria specific for osteoblast cell lines. Reverse transcription of
total mRNA isolated from BRITER cells cultured for two weeks in
mineralization media followed by PCR with primers specific for
osteoblast marker genes revealed that BRITER cells express
several known osteoblast markers e.g. Osx, ColIA1, BSP, Runx2,
Ocn and ALP (Figure 2A). RT-PCR for SV40- large T antigen
confirmed the integration and expression of the immortalizing
gene in BRITER cells (Figure 2A).
To assess the differentiation and mineralization ability of
BRITER cells we investigated the production of Alkaline Phospha-
tase (ALP), presence of Alizarin red and von Kossa positive
mineralized matrix in BRITER cells by culturing in mineralizing
mediafortwoweeks.WehavealsoquantifiedtheALPactivityinthe
cells cultured under the different conditions (Figure 2B) using
colorimetric method. While some ALP positive cells were observed
in untreated cells after the culture period, less number of ALP
positivecellsweredetectableupondepletionofendogenousBMPby
4-OHT treatment (compare panels a and b of Figure 2C, also see
Figure2B).ThenumberofALPpositivecellsincreasedsignificantly
when BMP-depleted (cultured in presence of 4-OHT) cells were
cultured in presence of exogenously added BMP2 protein (compare
panels b and c of Figure 2C, also see Figure 2B). Maximum number
of ALP positive cells were observed when BMP2 protein was added
to cells wherein the endogenous BMP was not depleted, i.e. when
cells were cultured in presence of BMP2 but absence of 4-OHT
(comparepanelscanddofFigure2C,alsoseeFigure2B).Unlikethe
presence of ALP activity or PSMAD 1/5/8 immunoreactivity, we
could not detect any alizarin red or von Kossa positive mineralized
nodules in BRITER cells cultured in absence of exogenously added
BMP. However, significant number of mineralized nodules were
observed in BMP depleted cells cultured in presence of exogenously
added BMP (compare panels e and f with panel g of Figure 2C for
alizarin red staining and compare panels i and j with panel k of
Table 1. Comparison of BRITER with previously reported osteogenic BMP reporter cell Lines.
S No. Cell Line
BMP
(ng/ml)
Fold Induction
(Normalized
FF Luc)
Fold Induction
(Relative Luc) Time (Hrs.)
Internal
Control Normalized by Ref.
1 C2C12 Cells stably
transfected with
BRE-FFLuc construct
50 5 N/A 16 None Untreated FFLuc value 12
10 2 N/A 16 None
2 C2C12 Cells stably
transfected with BRE-
FFLuc construct
19.5 1 N/A 15 None Untreated FFLuc value 14
3 C2C12 Cells stably
transfected with BRE-
FFLuc construct
100 35 N/A 24 None Untreated FFLuc value 13
0.5 2 N/A 24 None
4 BRITER
( BMP depletable
osteoblast, stably
transfetcted with dual
Luciferase construct)
100 35-50 45-100 3 SV-40 RR-Luc SV40-RRLuc as well as
untreated FFLuc values
In this
study
10 N/A 17 3 SV-40 RR-Luc
doi:10.1371/journal.pone.0037134.t001
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when cells were not depleted of endogenous levels of BMP i.e.
culturedinabsenceof4-OHT(comparepanelsgandhofFigure2C
for alizarin red stainingand comparepanels kand l ofFigure2Cfor
von Kossa staining). Our observations taken together strongly
suggest that BRITER cells are BMP-depletable and display BMP
dependent osteogenic activity.
Sensitivity of BRITER cells to exogenously added BMP
Wenextwantedtoinvestigate the responsivenessofBRITER cells
to exogenously added BMP of varying concentrations for which it
was necessarytoidentify thebesttime point tocarryout thisanalysis.
Thus we cultured BRITER cells in serum deprived media for
6 hours following which we added 100 ng/ml (High BMP) and
10 ng/ml (Low BMP) of BMP2 protein in two parallel sets of wells.
We cultured the cells further for 0.5, 1.5, 3, 6, 12 and 24 hours after
BMP addition. At the end of the intended culture duration dual
luciferase assay was performed with BRITER cell lysate. Cells
cultured in presence of high (Red line) or low BMP (Blue line)
concentration displayed maximum BMP responsiveness 3 hours
post BMP addition (Figure 3A). The FFLuc activity of BRITER cells
decreased sharply between six hours and twelve hours of BMP2
protein addition (Figure 3A). This sharp decline in FFLuc activity of
BRITER cells after six hours of BMP2 protein addition raised the
possibility that the BRE enhancer in BRITER cells gets sensitized
upon prolonged exposure to BMP2 protein. Alternatively, it is also
possible that under the assay conditions BMP2 activity decreases
with time. To distinguish between these two possibilities we have
conducted another time course experiment where FFLuc activity of
BRITER cells were measured after 0, 1, 1.5, 3, 4.5, 6, 7.5 and
9 hours after 100 ng/ml BMP2 protein addition. In a parallel
experiment, we added recombinant BMP2 protein (100 ng/ml) at
Figure 2. Characterization of BRITER cell line. (A) RT-PCR analysis of BRITER cell line for osteblast specific marker genes: Osterix (lane 1), ColIAI
(lane 2), BSP (lane 3), Runx2 (lane 4), Osteocalcin (lane 5), Alkaline Phosphatase (lane 6), Large T antigen (lane 7) and GAPDH (lane 8), respectively. (B)
Quantification of ALP activity of BRITER cell extracts cultured under indicated conditions. (C) Alkaline Phosphatase staining (a–d). Alizarin red staining
(e–h). von Kossa staining (i–l) of BRITER cell line cultured under following conditions ‘‘2BMP24 OHT’’ (a, e, i), ‘‘2BMP+4-OHT’’ (b, f, j), ‘‘+BMP+4
OHT’’ (c, g, k) and ‘‘+BMP24-OHT’’ (d, h, l). Scale bar 10 mm. Data shown is means 6 SEM of experiments carried out in triplicates.
doi:10.1371/journal.pone.0037134.g002
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relative luciferase activity at 9 hour time point i.e. 3 hours after
addition of the second dose of BMP2 protein (denoted as 9+ hour
time point). The relative luciferase activity at 9+ hour time point is
very similar to that at the 3 hour time point. If the BRE enhancer in
BRITERcellsbecamesensitizeduponBMP2proteinexposurethere
would not have been any further stimulation of FFLuc activity upon
BMP2 protein addition at the 6 hour time point. However, we
observed significantly more FFLuc activity in the 9+ hour time point
sample as compared to that of the 9 hour time point sample (Figure
S3A). In fact the FFLuc activity of 9+ hour time point sample is close
to that of the 3 hour time point sample (Figure S3A). This suggests
that the sharp decline in FF-Luc activity in BRITER cells after
6 hours of BMP2 protein addition is a reflection of decline of BMP2
activity with time under the assay conditions and not a result of
sensitization of BRE enhancer. It should also be noted that in this
time course also the highest FFLuc activity was observed 3 hours
after BMP2 protein addition (Figure S3A). Therefore we decided to
assess BMP responsiveness of BRITER cells 3 hours post BMP2
protein addition in all subsequent experiments.
To ensure that BRITER has a stable phenotype we cultured
BRITER cells for 25, 30, 35, 40 or 45 passages and froze several
aliquotsatallthesedifferent passages.Weconducteddual luciferase
assays with BRITER cells at these different passage numbers
3 hourspost BMP2 proteinaddition. The relativeluciferase activity
produced by BRITER cells upon stimulation by BMP2 protein was
highly comparable between all these different samples suggesting
that BRITER cells have stable phenotype vis-a `-vis response to
exogenously added BMP2 protein (Figure S3B).
To investigate the sensitivity of BRITER cells to exogenously
added BMP, we cultured BMP-depleted (24 hr. 4-OHT treated)
or untreated BRITER cells for 3 hours in presence of exogenously
added BMP2 protein with concentrations ranging from 0.1 ng/ml
to 1000 ng/ml. Irrespective of whether the cells were BMP
depleted or not, we observed significant stimulation of FFLuc
activity only when the exogenously added BMP2 protein
concentration was more than 5 ng/ml. The normalized FFLuc
activity (FFLuc [+BMP]/FFLuc [2BMP]) increased linearly
between 10 ng/ml to 1000 ng/ml of exogenously added BMP2
protein concentration. The normalized FFLuc activity was not
saturated within the BMP dosage range of our investigation
(Figure 3B). It should be noted that the normalized FFLuc activity
in presence of any given concentration of BMP was always more
when cells were not depleted of endogenous BMP. Further, the
absolute value of FFLuc activity is significantly more if endogenous
BMP activity is not depleted (Inset, Figure 3B).
Measuring normalizedFFLucactivityinpresence andabsenceof
exogenously added BMP is a sensitive measure of exogenously
added BMP activity. However, in the context of a drug screen or
functional genetics screen, it is desirable to have an internal control
to ensure that the variation in FFLuc activity is not an indirect
consequence of altered cell proliferation or basal level of transcrip-
tion due to chemical or genetic modification of the cell line. For this
purpose, we plotted the relative luciferase activity (FFLuc/RRLuc)
graph. This dosage response graph clearly demonstrates that
RRLuc activity is not influenced by exogenously added BMP
(Figure 3C). It should be noted that the relative luciferase activity in
presence ofanygiven concentrationofBMPwasalways morewhen
cells were not depleted of endogenous BMP.
While normalized FFLuc activity (FFLuc [+BMP]/FFLuc
[2BMP]) is a measure of response to exogenously added BMP, it
does not provide an estimation of non-specific activation of FFluc.
On the other hand relative luciferase (FFLuc/RRLuc) activity
reflects specific stimulation of BRE enhancer, it does not provide an
estimation of endogenous (basal) BMP activity. To compensate for
both these variables and to assess the sensitivity of BRITER cells
with respect to exogenously added BMP, we plotted a graph of
normalized relative luciferase activity using the formula (FFLuc
[+BMP]/FFLuc [2BMP])/(RRLuc [+BMP]/RRLuc [2BMP]). It
should be noted that, in contrast to Figure 3B and Figure 3C,
normalized relative luciferase activity in presence of any given
concentration of BMP was always more when cells were depleted of
endogenous BMP. This graph clearly demonstrated that BRITER
cells are relatively more sensitive to exogenously added BMP2
protein when endogenous BMP activity is depleted by 4-OHT
mediated recombination of Bmp2 and Bmp4 loci (Figure 3D).
Discussion
The objective of this work was to generate a robust, sensitive
and internally controlled BMP reporter osteoblast cell line suitable
for chemical or molecular genetic screen of BMP signaling
modifiers. For this purpose we immortalized mouse calvarial
osteoblast cells isolated from a tamoxifen inducible Bmp2; Bmp4
double conditional knockout mouse strain and stably transfected it
with a dual luciferase reporter construct. BMP reporter cell lines
have been reported earlier in the literature [12,13,14] where BRE-
FFLuc reporter construct has been stably integrated into C2C12
cell line. These cell lines provided very sensitive assays for
bioactive BMP molecules. The sensitivity and robustness of our
cell line is comparable to (if not more) the ones reported earlier.
However, unlike the previously reported cell lines BRITER has an
in-built internal control to enable specific detection of BMP
activity modifiers. Also, the rapidity with which BRITER responds
to exogenously added BMP protein suggests that stimulation of
BRE-FFLuc in BRITER cells is a direct consequence of activation
of BMP signaling. This is in stark contrast to the previously
reported cell lines where BMP responsiveness was apparent only
after 15–24 hours (Table 1). In the sections below we have
discussed in detail, several aspects of the BRITER cell line such as
robustness, sensitivity etc., which demonstrates that because of the
genetic tools embedded in the cell line, BRITER is more
appropriate for small molecule BMP agonist screening as well as
functional genomic screening (comparison of BRITER cells with
previously reported cell lines is presented in Table 1).
BRITER cells robustly respond to exogenously added BMP2
protein. We have observed a 94 fold and 51 fold stimulation of
FFLuc activity in response to 100 ng/ml of exogenously added
BMP2 protein in 4-OHT untreated and 4-OHT treated BRITER
cells, respectively. To the best of our knowledge, the fold
stimulation of reporter gene activity we observed with BRITER
cell line is significantly more than the earlier reports [12,13,14].
Contrary to the previously reported cell lines, BRITER responds
to exogenously added BMP2 protein within 1 hour with peak
activity observed after 3 hours of BMP2 protein addition thus
reducing the possibility of secondary factors influencing BRE-
FFLuc activity [12,13,14].
InthiscontextitisworthcomparingthepropertiesofC2C12cells
withthatofanosteoblastderivedcelllinelikeBRITER.C2C12cells
are not intrinsically osteogenic i.e they cannotproduce ALP activity
unless stimulated by exogenously added BMP protein [39]. In
contrast, an osteoblast derived cell line like BRITER can produce
ALP activity on its own [40] (also see Figure 2C, panel a). This
suggests that unstimulated C2C12 cells do not have all the
components necessary to carry out an osteogenic program and gets
reprogrammed to osteogenic fate upon exposure to exogenously
addedBMPwhileanosteoblastderivedcelllinelikeBRITERhasall
the components necessary to carry out an osteogenic program in
BMP Responsive Osteoblast Reporter Cell Line
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cell line and BRITER cell line perhaps accounts for the stark
difference in the kinetics of BMP responsiveness.
The readoutof BMP signaling in BRITER cells is FFLuc activity.
However, FFLuc activity may vary due to factors other than the
ones affecting BMP signaling directly. BRE-FFLuc activity will
depend on cell number and status of global gene expression. In the
context of a chemical or molecular genetic screen, there may be
factors affecting cell number and status of global gene expression
thus giving false positive results. However in our construct, the
production of Renilla luciferase is under the control of SV40
promoter, a non-BMP responsive constitutive promoter. Any
change in the RRLuc activity would be indicative of a drug or
geneticfactorhavingactivitynotspecifictoBMPsignalingpathway.
We incorporated constitutive promoter driven RRLuc activity in
BRITER to normalize for these non-specific factors. In our hands,
under varying conditions RRLuc activity never varied more than 2
fold while FFLuc activity varied up to 300 fold strongly suggesting
that BRITER cells can efficiently normalize for false positive
indications and thus can significantly reduce downstream work
following a screen. None of the previously reported osteogenic
BMP-reporter cell lines contained such an in-built internal control
(Table 1). Furthermore, BRITER responds to BMP in a dose
dependent manner for upregulation of ALP activity (Figure 2B and
Figure 2C). Thus ALP activity may serve as a secondary screen
criteria further eliminating the need of extensive experimentation to
narrow down the targets for further study.
BRITER cell line is designed for the purpose of chemical or
molecular genetic screen of potential BMP signaling modifiers. It is
therefore necessary to have a large dynamic range of the assay.
Three lines of arguments taken together inspired us to create a cell
line that can be depleted of endogenous BMP activity for the
purpose of increasing the dynamic range of our assay system: 1.
BMP signaling is necessary for bone formation [6], 2. BMP2 and
Figure 3. (A) Time course analysis showing relative FFLuc activity in presence of 100 ng/ml (red line) and 10 ng/ml (blue line) BMP2 concentrations
at different time points indicated. (B) Normalized FFLuc activity, (Inset showing absolute values of FFLuc activity) after 3 hours of stimulation with
different BMP2 concentrations in presence (blue line) or absence (red line) of 4-OHT. (C) Relative luciferase activity after 3 hours of stimulation with
different BMP2 concentrations in presence (blue line) or absence (red line) of 4-OHT. (D) Normalized relative luciferase activity after 3 hours of
stimulation with different BMP2 concentrations in presence (blue line) or absence (red line) of 4-OHT. Data shown are means 6 SEM of three
independent experiments carried out in triplicates.
doi:10.1371/journal.pone.0037134.g003
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[6], and 3. Any osteogenic cell line is expected to produce
endogenous BMP under osteogenic condition and hence may
provide background BMP signaling activity. We used available
Bmp2; Bmp4 double conditional knockout mouse strains and
tamoxifen inducible Cre expressing mouse strain to engineer the
necessary genetic background for depleting endogenous BMP
signaling to a large extent.
Inthisstudywehavedefinedsensitivityasaresponsetoexogenous
BMP indicated by the normalized relative luciferase activity (FFLuc
[+BMP]/FFLuc [2BMP])/(RRLuc [+BMP]/RRLuc [2BMP]).
Normalized relative luciferase value takes into account two variables
that can affect the apparent sensitivity of BRITER cells to
exogenously added BMP namely, endogenous BMP activity and
non-specific stimulation of BRE-FFLuc activity. We observed that
the sensitivity to exogenously added BMP is 1.5 to 2 fold higher
(Figure 3D) upon depletion of endogenous BMP (+4-0HT). What
was somewhat surprising is that the increased sensitivity is more
apparent when exogenously added BMP concentration is 5 ng/ml
or higher. When we conceived the experiment, we expected the
sensitivity towards exogenously added BMP to be more at lower
concentration of BMP (i.e. BMP depleted condition), however our
observation is contrary to our expectations. This apparent contra-
diction may be a result of one of the two following factors
i) The specific activity of BMP that we are using in these assays
is not very high and the effect of exogenously added BMP is
only apparent at a concentration higher than critical threshold
of 5 ng/ml. However, this is unlikely to be the case as the fold
change stimulation of FFLuc value with or without BMP
addition is significantly more than the values reported in the
literature earlier.
ii) Alternatively, it is possible that depletion of endogenous BMP
for 24 hrs (by maintaining the cell line in presence of 4-
Hydroxytamoxifen) causes depletion of other active molecules
required for transcription and translation of Firefly luciferase
upon BMP signaling. In fact, existing literature supports such
a hypothesis. Runt-related gene 2 (Runx2), a downstream
target gene of BMP signaling is shown to interact with
SMAD1 and SMAD5 and regulate BMP signaling
[41,42,43,44]. Hence, lowering the levels of endogenous
BMP can potentially lower the expression of Runx2 and/or
other regulators of BMP signaling limiting the ability of
BRITER cells to respond to BMP signaling below a critical
threshold of exogenously added BMP concentration.
Cellbased assays usingluciferasereporter hasbeen successfullyused
earlier for identification of novel drug candidates [45,46,47]. Similarly,
cell based assays using luciferase reporter has been successfully used
earlier for genome-wide RNAi screening to investigate several cellular
pathways [48,49,50]. BRITER is thus equipped to be used for
screening modifiers of BMP signaling pathway.
In conclusion, BRITER is highly sensitive to exogenously added
BMP, responds robustly and specifically to active BMP signaling.
This cell line is capable of undergoing osteogenic differentiation in
graded response to active BMP signaling and is suitable for
chemical and molecular genetic screens which may help elucidate
the molecular players involved in BMP signaling pathway and/or
identification of clinically important drug molecules.
Supporting Information
Figure S1 Time course of luciferase activity in C2C12
cells. C2C12 cells were transiently transfected with dual luciferase
construct (pBFIR) and treated with 100 ng/ml BMP2 protein or
vehicle. Dual luciferase assay was conducted after indicated
duration of incubation (in hrs). Green line depicts normalized (with
BMP2 untreated cell lysate values) Renilla luciferase values. Red
line depicts normalized (with BMP2 untreated cell lysate values)
Firefly luciferase values. Blue line depicts relative luciferase
(FFLuc/RRLuc) values.
(TIF)
Figure S2 4-OHT induced recombination in BRITER
cell line. (A) Schematic showing the genomic configuration for
Bmp2 and Bmp4 conditional alleles. The primers for genotyping
are shown as red arrows. (B) Bmp2 and Bmp4 floxed alleles before
and after recombination in absence and presence of 4-OHT,
respectively. Amplicon for Cre transgene is used as loading
control. (C) Bmp2 and Bmp4 mRNA levels before and after
recombination in absence and presence of 4 OHT, respectively.
RT-PCR of Gapdh mRNA has been used as loading control.
(TIF)
Figure S3 (A) BRE enhancer does not become sensitized
due to prolonged exposure to recombinant BMP2
protein. Time course analysis showing relative FFLuc activity
in presence of 100 ng/ml BMP2 concentrations at different time
points indicated. For the ‘‘9+’’ hour time point sample
recombinant BMP2 protein (100 ng/ml) was added at 0 hour
time point and then again at 6 hour time point and relative
luciferase activity was measured at 9 hour time point. (B)
BRITER has stable phenotype. Relative luciferase activity
of BRITER cells at different passage numbers (as indicated) was
measured after treating the cells with 100 ng/ml of recombinant
BMP2 protein for three hours. Relative luciferase activity of
BRITER cells at passage number 25 (25 UT) and 45 (45 UT) were
also measured with untreated cells.
(TIF)
Table S1 Description of primers used in this study.
(DOC)
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